likely

Oncotelic and Sapu Nano Announce DeciparticleTM Led Biomarker Framework Identifying Tumors Most Likely to Respond to IV Sapu003, an Intravenous Everolimus Nanomedicine

AGOURA HILLS, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) 45% owned Joint Venture, Sapu Nano today…

1 week ago

Bybit x FXStreet TradFi Report: Japan’s Historic Leadership Shift Sparks Nikkei Rally and Yen Weakness

DUBAI, UAE , Oct. 10, 2025 /PRNewswire/ -- Bybit, the world's second-largest cryptocurrency exchange by trading volume, has released a new…

2 months ago

DoubleLine Foresees Further Treasury Yield Curve Steepening, Risk of Elevated Term Premium

TAMPA, Fla., Oct. 3, 2025 /PRNewswire/ -- The U.S. Treasury yield curve, DoubleLine Global Bond Portfolio Manager Bill Campbell writes in a…

2 months ago

Strong Lamborghini SC63 pace goes unrewarded in the Battle on the Bricks at Indianapolis

#63 pairing of Mortara-Grosjean finish 10th in penultimate round of the year after late cautionSant’Agata Bolognese/Indianapolis, 21 September 2025 –…

3 months ago

EADV Congress 2025: Atopic eczema linked to significantly higher risk of suicidal thoughts

PARIS, Sept. 17, 2025 /PRNewswire/ -- A new international study presented today at the European Academy of Dermatology and Venereology (EADV)…

3 months ago

Huion Launches 2025 Back-to-School Deals: Promotions for Creative Tools for Students & Teachers

LOS ANGELES, Aug. 15, 2025 /PRNewswire/ -- With August here, the Back-to-School season is officially underway. Students, parents, and teachers…

4 months ago

Cornerstone VR Sponsors Muay Thai Athlete Gene Smith to Support Youth Empowerment and Combat Knife Crime

Tuesday 8 July, 2025 According to the Youth Endowment Fund’s Children, Violence and Vulnerability Report 5, children most vulnerable to…

5 months ago

AB Science: Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer

PRESS RELEASE MASITINIB RECEIVES FDA AND EMA AUTHORIZATION FOR CONFIRMATORY PHASE 3 TRIAL IN METASTATIC CASTRATE-RESISTANT PROSTATE CANCER, WITH BIOMARKER-DRIVEN…

5 months ago